Prediction of human pharmacokinetics—evaluation of methods for prediction of hepatic metabolic clearance
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Methods for prediction of hepatic clearance (CLH) in man have been evaluated. A physiologically-based in-vitro to in-vivo (PB-IVIV) method with human unbound fraction in blood (fu,bl) and hepatocyte intrinsic clearance (CLint)-data has a good rationale and appears to give the best predictions (maximum ∼2-fold errors; < 25% errors for half of CL-predictions; appropriate ranking). Inclusion of an empirical scaling factor is, however, needed, and reasons include the use of cryopreserved hepatocytes with low activity, and inappropriate CLint- and fu,bl-estimation methods. Thus, an improvement of this methodology is possible and required. Neglect of fu,bl or incorporation of incubation binding does not seem appropriate. When microsome CLint-data are used with this approach, the CLH is underpredicted by 5- to 9-fold on average, and a 106-fold underprediction (attrition potential) has been observed. The poor performance could probably be related to permeation, binding and low metabolic activity. Inclusion of scaling factors and neglect of fu,bl for basic and neutral compounds improve microsome predictions. The performance is, however, still not satisfactory. Allometry incorrectly assumes that the determinants for CLH relate to body weight and overpredicts human liver blood flow rate. Consequently, allometric methods have poor predictability. Simple allometry has an average overprediction potential, > 2-fold errors for ∼1/3 of predictions, and 140-fold underprediction to 5800-fold overprediction (potential safety risk) range. In-silico methodologies are available, but these need further development. Acceptable prediction errors for compounds with low and high CLH should be ∼50 and ∼10%, respectively. In conclusion, it is recommended that PB-IVIV with human hepatocyte CLint and fu,bl is applied and improved, limits for acceptable errors are decreased, and that animal CLH-studies and allometry are avoided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A General Model for the Origin of Allometric Scaling Laws in Biology
West, G. B., Brown, J. H., & Enquist, B. J. (1997) · Science · doi:10.1126/science.276.5309.122 · Cited by 5,016
Scaling: Why is Animal Size so Important?
Schmidt-Nielsen, K. (1984) · doi:10.1017/cbo9781139167826 · Cited by 2,677
Kleiber, M. (1932) · Hilgardia · doi:10.3733/hilg.v06n11p315 · Cited by 2,222
Kansy, M., Senner, F., & Gubernator, K. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970530e · Cited by 1,304 · cited 1×
“However, nine of 14 compounds had incomplete GI absorption (fa-values in man 0.80–0.99) (Palm et al 1997; Kansy et al 1998; Wessel et al 1998; Balon et al 1999; Pérez et al 2004), and extrahepatic elimination has been found for at least four of the test drugs (Thummel et al 1997; Goodman Gilman…”
BackgroundInfluentialObach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925 · cited 9×
“Correlations between in-vitro and in-vivo liver metabolism data have been used for prediction of the in-vivo CLH, but due to a neglect of some essential factors predictions are poor (Kroemer et al 1992; Hoener 1994; Houston 1994; Ubeaud et al 1995; Lavé et al 1997b; Ito et al 1998; Iwatsubo et al 1997; Clarke & Jeffre…”
BackgroundMethodInfluentialPang, K. S., & Rowland, M. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059688 · Cited by 797 · cited 7×
“The parallel-tube model assumes that the liver is composed of a series of identical and parallel tubes, along which drug concentration decreases progressively in the direction of the hepatic blood flow (Pang & Rowland 1977).”
BackgroundMethodInfluentialInterspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648 · cited 3×
“The relationship between skeletal size and body weight (BW) was discussed by Galileo (Boxenbaum 1982) as early as 1637, and Rubner (1983) explored and found a relationship between basal metabolic rate (heat production and oxygen utilization) and body weight of dogs.”
BackgroundMethodMetabolic zonation of the liver: Regulation and implications for liver function
Gebhardt, R. (1992) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(92)90055-5 · Cited by 607 · cited 1×
“Based upon an average hepatocyte volume of 4000 mm3 (or 4 × 10−9 mL) per cell (Gebhardt 1992), and a cell density of 1, 2 and 5 million cells (mL medium)−1, hepatocytes would occupy approximately 4, 8 and 20 per mL of the volume of the incubation system, respectively.”
BackgroundPrediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479 · cited 8×
“Iwatsubo et al (1997) and Ito et al (1998) compared human microsome in-vitro CLint (MFM) and in-vivo CLint (calculated using CL in-vivo and fu,bl-data, and well-stirred, parallel-tube and dispersion equations) for 29 substances, and found a poor correlation.”
BackgroundMethodInfluentialDedrick, R. L. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059667 · Cited by 397 · cited 9×
“The data collected by those authors demonstrated that 80–90% of compounds that were predicted (from animal data) to have low CL in man experimentally demonstrated low CL. Correct CL classification for drugs with moderate and high CL was lower, approximately 20–30% and 30–50%, respectively.”
BackgroundInfluentialInterspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257
Human hepatocytes as a tool for studying toxicity and drug metabolism
Gomez-Lechon, M., Donato, M., Castell, J., & Jover, R. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489424 · Cited by 242
Ward, K. W., & Smith, B. R. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.603 · Cited by 212
Lave, T. H., Dupin, S., Schmitt, C., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960440h · Cited by 184 · cited 7×
“Lavé et al (1997b) showed a log–log correlation between human hepatocyte in-vitro CLint and human in-vivo EH for 19 compounds.”
BackgroundResultInfluentialChiou, W. L., Jeong, H. Y., Chung, S. M., & Wu, T. C. (2000) · Pharmaceutical Research · doi:10.1023/a:1007552927404 · Cited by 182
Lav??, T., Coassolo, P., & Reigner, B. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936030-00003 · Cited by 162 · cited 7×
“Underprediction of CLu of similar size was shown by Lavé et al (1999a).”
BackgroundMethodResultInfluentialCaldwell, G. W., Masucci, J. A., Yan, Z., & Hageman, W. (2004) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190588 · Cited by 148
A NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALING
Tang, H., & Mayersohn, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004143 · Cited by 141
The Pharmacokinetic Principles Behind Scaling from Preclinical Results to Phase I Protocols
Mahmood, I., & Balian, J. D. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936010-00001 · Cited by 112
Lavé, T., Dupin, S., Schmitt, C., Valles, B., Ubeaud, G., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Pharmaceutical Research · doi:10.1023/a:1012036324237 · Cited by 106 · cited 7×
“Lavé et al (1997b) showed a log–log correlation between human hepatocyte in-vitro CLint and human in-vivo EH for 19 compounds.”
BackgroundResultInfluentialMahmood, I., & Balian, J. D. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js950400y · Cited by 105 · cited 2×
“…1992; Hinderling et al 1993; Gascón et al 1994; Jezequel 1994; Cruze et al 1995; Lavé et al 1995a, 1996c, 1997a, 1999a, b; Grene-Lerouge et al 1996; Mahmood & Balian 1996a, b, c, 1999; Obach et al 1997; Sanwald-Ducray & Dow 1997; van Hoogdalem et al 1997; West et al 1997; Chiou et al 1998; Mahmood…”
BackgroundNagilla, R., & Ward, K. W. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20169 · Cited by 96
Prediction of Hepatic Metabolic Clearance: Comparison and Assessment of Prediction Models
Zuegge, J., Schneider, G., Coassolo, P., & Lav??, T. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140070-00006 · Cited by 92 · cited 6×
“In a study by Zuegge et al (2001), the predictability of a supervised ANN method was compared with allometric scaling with correction for interspecies in-vitro CLint-differences, and PB-IVIV (hepatocytes) prediction with and without a scaling factor.”
BackgroundMethodInfluentialTang, H., & Mayersohn, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20481 · Cited by 89 · cited 7×
“The compound with the largest overprediction error (5800-fold), the protein kinase inhibitor UCN-01, was predicted to have a CL 35-fold greater than the QH (Tang & Mayersohn 2006a).”
BackgroundMethodInfluentialMahmood, I., & Balian, J. D. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00339-6 · Cited by 72
Mahmood, I. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991773320 · Cited by 59 · cited 2×
“…1996; Mahmood & Balian 1996a, b, c, 1999; Obach et al 1997; Sanwald-Ducray & Dow 1997; van Hoogdalem et al 1997; West et al 1997; Chiou et al 1998; Mahmood 1998, 1999, 2001, 2002b, 2004; Björkman & Redke 2000; Feng et al 2000; Hu & Hayton 2001; Liu & Chen 2001; Påhlman et al 2001; Ward et al…”
BackgroundInterspecies Scaling: Predicting Oral Clearance in Humans
Mahmood, I. (2002) · American Journal of Therapeutics · doi:10.1097/00045391-200201000-00008 · Cited by 33 · cited 4×
“The allometric technique has also been applied to scale the oral CL (CL/F; where F is the oral bioavailability) and CLu/F for compounds that cannot or have not been given intravenously (Mahmood 1997; Feng et al 2000; Mahmood 2002a; Wajima et al 2003; Tang & Mayersohn 2006b).”
BackgroundMethodInfluentialMahmood (2002) · Drug Metabolism and Drug Interactions · doi:10.1515/dmdi.2002.19.1.49 · Cited by 29
Chiou, W. L., & Hsu, F.-H. (1988) · Pharmaceutical Research · doi:10.1023/a:1015935206569 · Cited by 28 · cited 2×
“Chiou & Hsu (1988) found good predictability of CLu (from rat to man) and poor predictability of CL for 15 extensively metabolized compounds.”
Background
Cited by
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300
Upreti, V. V., Wang, J., Barrett, Y. C., Byon, W., Boyd, R. A., Pursley, J., LaCreta, F. P., & Frost, C. E. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12114 · Cited by 269
Ring, B. J., Chien, J. Y., Adkison, K. K., Jones, H. M., Rowland, M., Jones, R. D., Yates, J. W. T., Ku, M. S., Gibson, C. R., He, H., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22552 · Cited by 206
Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation
Zou, P., Yu, Y., Zheng, N., Yang, Y., Paholak, H. J., Yu, L. X., & Sun, D. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9332-y · Cited by 138
Metadata
- Authors
- Fagerholm, U.
- Venue
- Journal of Pharmacy and Pharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-01
- Volume
- 59
- Issue
- 6
- Pages
- 803-828
- ISSN
- 0022-3573 (ISSN-L)
- 2042-7158
- OpenAlex
- W1993437269
- Cited by
- 76
- References
- 31
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.